NUMI expansion NUMI announces plans to significantly expand its psychedelics research laboratory by late 2021. A 7,500 square foot addition alongside the expansion, NUMI also receives amendments from Health Canada to allow production, sale, and export of several psychedelics including Ketamine, LSD, Mescaline, DMT, and psilocybin. The leaders in psychedelic research will be receiving 1.2 million in new equipment, As they continue to optimize their ability to make innovating research and expanding standardized test methods for a wide variety psychedelics.